Association of Hepsin gene variants with prostate cancer risk and prognosis

Prostate

Volumn 70, Issue 9, 2010, Pages 1012-1019

  Holt, Sarah K ^a   Kwon, Erika M ^b,c   Lin, Daniel W ^a,d   Ostrander, Elaine A ^b   Stanford, Janet L ^a,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Case control; Hepsin; Prostate neoplasm; Single nucleotide polymorphism

Indexed keywords

HEPSIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; GENE EXPRESSION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK ASSESSMENT; SEER PROGRAM; SERINE ENDOPEPTIDASES;

EID: 77952898428     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21135     Document Type: Article

References (21)

1. Wu Q, Parry G: Hepsin and prostate cancer. Front Biosci 2007; 12:5052-5059.
2. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vadioukhin V: Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004;6:185-195. (Pubitemid 39485690)
3. Vasioukhin V: Hepsin paradox reveals unexpected complexity of metastatic process. Cell Cycle 2004;3:1394-1397.
4. Xuan JA, Schneider D, Toy P, Lin R, Newton A, Zhu Y, Finster S, Vogel D, Mintzer B, Dinter H, Light D, Parry R, Polokoff M, Whitlow M, Wu Q, Parry G: Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res 2006; 66:3611-3619.
5. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, RubinMA,ChinnaiyanAM:Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-826.
6. Witte JS, Elston RC, Lin J, Suarez BK, Broman KW, Burmester JK, Weber JL, Catalona WJ: Genome-wide scan for prostate cancer-aggressiveness loci. Am J Hum Genet 2000;67:92-99.
7. Witte JS, Suarez GK, Thiel B, Lin J, Yu A, Banerjee TK, Burmester JK, Casey G, Catalona WJ: Genome-wide scan of brothers: Replication and fine mapping of prostate cancer susceptibility and aggressiveness loci. Prostate 2003;57:298-308.
8. Pal P, Xi H, Kaushal R, Sun G, Jin CH, Jin L, Suarez BK, Catalona WJ, Deka R: Variants in the HEPSIN gene are associated with prostate cancer in men of European origin. Hum Genet 2006; 120:187-192.
9. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK: Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999;8:881-886.
10. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL: Statin use and risk of prostate cancer: Results from a population-based epidemiologic study. Am J Epidemiol 2008;168:250-260. (Pubitemid 352019786)
11. Clayton D, Leung HT: An R package for analysis of whole-genome association studies. Hum Hered 2007;64: 45-51. (Pubitemid 46684918)
12. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA: Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004;74:106-120. (Pubitemid 38085242)
13. Chapman JM, Cooper JD, Todd JA, Clayton DG: Detecting disease associations due to linkage disequilibrium using haplotype tags:Aclass of tests and the determinants of statistical power. Human Heredity 2003;56:18-31.
14. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265. (Pubitemid 40202029)
15. Li SS, Khalid N, Carlson C, Zhao LP: Estimating haplotype frequencies and standard errors for multiple single nucleotide polymorphisms. Biostatistics 2003;4:513-522.
16. Harrell FE. Regression modeling strategies: With applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001. 147-156.
17. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J: Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001;61:5692-5696.
18. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Loening SA, Diamandis EP: Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol 2004;171:187-191.
19. Moran P, Li W, Fan B, Vij R, Eigenbrot C, Kirchholfer D: Prourokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem 2006;281:30439-30446.
20. Ogura Y, Matsunaga Y, Nishiyama T, Amano S: Plasmin induces degradation and dysfunction of laminin 332 (laminin 5) and impaired assembly of basement membrane at the dermal-epidermal junction. Br J Dermatol 2008;159:49-60. (Pubitemid 351874464)
21. Tripathi M, Nandana S, Yamashita H, Ganesan R, Kirchhofer D, Quaranta V: Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. J Biol Chem 2008; 283:30576-30584.